ࡱ> FHE[ R$bjbj88ΐΐ 44}}}}}8$,Bl////ccc$PB}ccccc}}//4cZ}/}/c/0$\/0BK}ccccccccccBccccccccccccc4 C: Dear Friends and Colleagues, We extend a warm welcome to the leading scientists, doctors, industrialists and young researchers to BIT Life Sciences 1st Annual World Congress of Immunodiseases and Therapy 2010 (WCIT-2010) with the theme of Boosting Health and Vitality, which will take place in Beijing, China on May 15-17, 2010. With your great contributions in the study and research on immunology, you are expected to take part in this international and  HYPERLINK "javascript:void(0)" compositive conference. The program track info at the bottom of the e-mail is for your reference. WCIT is a focused conference to present and deliberate the advances in immunology, which is significant, timely and important to the health of humanity. The well selected topics cover across disciplinary breaking, from concept to therapy. It is anticipated over 500 global specialists to get together to present and share their cutting-edge technologies and up-to-date researches in an innovative and invigorating combination of presentations, symposia, discussions, panel discussion sessions and associated young scientist poster sessions along with exhibition of technology and new products. The comprehensive and intellectually stimulating scientific program of the first annual will embrace a broad spectrum of topics in basic science, medical research, diagnosis, prevention, clinical treatment and therapy of immune diseases. We believe that WCIT-2010 will definitely provide you an ideal platform for promoting ground breaking research and seeding potential collaborations for relevant parties of tailored interests not only in R & D areas but also the industrial and medical sectors. The Initiative of WCIT-2010 will include both oral and poster presentations from academic and industrial settings. We hope to set a stage for all the medical doctors, the academicals, the clinical and the industrial researchers to make your research and innovations known with equal opportunity, means to join this event actively. The capital city, Beijing has long been the political, cultural, scientific and diplomatic center of China. It is both a tribute to China's proud history and a gateway to China's future. Beijing Olympics brought the world a great surprise for the Olympics opening ceremony, WCIT-2010 will be held in Beijing International Convention Center (BICC) which located very near to The National Olympic Sports Center, it's a great advantage to see this amazing place. Also, May is the most pleasant season in spring, you are encourage to have lecture tour to other cities in China. We look forward to seeing you in Beijing for a stimulating and enjoyable conference! Below is the program track info. Kayla Liu Program Coordinator The Organizing Committee of WCIT-2010 Tentative Program Symposium 1: Research Frontiers on Immune Diseases Session 1-1: The Immunity Diseases Molecular Mechanisms Session 1-2: Immunopathology, Etiology and Pathogenic Role of Complement Session 1-3: Genetics of Immune and Autoimmunity Diseases Session 1-4: Cell and Molecular Biology of Autoimmunity Session 1-5: Tumor Immunology Session 1-6: Innate to Acquired (Adaptive) Immunity and Diseases Session 1-7: Toll-like Receptors and Pattern Recognition Receptors Session 1-8: Immune Signal Transduction and Cross-talk Session 1-9: Immune Regulations- Regulatory T Cells and T Cell Subsets Session 1-10: Dendritic Cells, Macrophages and other Innate Immune Cells Session 1-11: Human Immunology and Immunodeficiencies Session 1-12: Hypersensitivity, Antigen Processing and Presentation Session 1-13: Immunological Inflammations and Vascular Injury Session 1-14: Neuroimmunology, Neuroendocrine Immunology and Psychoneuroimmunology Session 1-15: Natural Killer Cells, Apoptosis & Immunity Session 1-16: Infection and Immunity, Epidemiology of Immune Diseases Session 1-17: Prophylaxis and Intervention Session 1-18: Mucosal Immunology Session 1-19: Immunochemistry & Immunobiology Session 1-20: ImmuneTolerance in Autoimmune Disease Symposium 2: Leading Technologies in Immunology Session 2-1: System Biology and Computational Immunology Session 2-2: Hybridoma Technology Session 2-3: Sensitivity and Accuracy in Imaging Immunity Session 2-4: Immunogenomics & Immunoproteomics Session 2-5: Biochips, Microarray Based Technology Session 2-6: New ImmuneIntervention Technologies Session 2-7: Small RNAs in Development and Immune Diseases Session 2-8: Nucleic Acids in Innate Immunity Session 2-9: The Stem Cells and Implications in Immune Diseases Session 2-10: The SCID Mouse as Model of Immune Diseases  Symposium 3: Immune Disease Drug Discovery & Development Session 3-1: Molecular Targets and Biomarkers of Immunotherapeutics Session 3-2: Computer Aided Drug Design & Medicinal 91AV Session 3-3: Immunopharmacology Session 3-4: Immunosuppression and Immunotherapy Development Session 3-5:Cytokines, Chemokine and Cell Adhesion Molecules and Drug Discovery Session 3-6: GeneandCellTherapy Session 3-7: MonoclonalAntibodyand Antibody Engineering Session 3-8: Innate Immunity and Novel Vaccines Session 3-9: Novel Drug Delivery Systems of Immunotherapeutics Session 3-10: Traditional Medicines for Immune and Inflammatory Diseases Symposium 4: Medical Research and Immune Diseases Session 4-1: Immunity and Emerging Infectious Disease Session 4-2: HormonesandImmuneResponse Mediated Diseases Session 4-3: Allergy, Asthma & Clinical Immunology Session 4-4: Autoimmunity Mediated Diseases Session 4-5: Lymphocyte Development and Functions in Immune Diseases Session 4-6: Immunosenescence and Clinical Applications Session 4-7: Immunity and Aging Session 4-8: Reproductive Immunology Session 4-9: Neonatal and Maternal Immunization Session 4-10: Translational Immunology Symposium 5: Diagnostics & Immunotherapy of Major Diseases Session 5-1: Biomarkers for Molecular Diagnostics of Immune Diseases Session 5-2: Insulin-Dependent Diabetes Mellitus Session 5-3: Allergy, Asthma and Rheumatoid Arthritis Session 5-4: Inflammatory Bowel Disease and Ocular Inflammation Session 5-5: Vasculitis and Cardiovascular Diseases Session 5-6: Lung Inflammation and Fibrosis Session 5-7: Autoimmune Hepatitis and Chronic Liver Diseases Session 5-8: Multiple Sclerosis, Scleroderma, Myasthenia Gravis, and Neuromuscular Diseases Session 5-9: Systemic Lupus Erythematosus and and Other Connective Tissue Diseases Session 5-10: Psoriasis, Allergic Skin Diseases and Immunodermatology Session 5-11: Immunotherapy on Reemerging TB and Malaria Session 5-12: Immunological Renal Diseases, and Organ Transplant Rejection Session 5-13: Major Cancers- Breast Cancer Session 5-14: Major Cancers-Head, Brain and Neck Cancers Session 5-15: Major Cancers- Cervical and Ovarian Cancer Session 5-16: Major Cancers- Pancreatic , Prostate, and Renal Cancer Session 5-17: Major Cancers- Leukemia, Lymphoma & Melanoma Session 5-18: Major Cancers- Lung Cancer Session 5-19: Major Infectious Diseases- HIV/AIDS and Other Viral Infections Session 5-20: Major Infectious Diseases-Resistant Bacterial Infections Symposium 6: Benchmark Analysis and Case Studies Session 6-1: Anticancer Drugs Session 6-2: Anti-inflammatory Drugs Session 6-3: Anti-allergy and Asthma Drugs Session 6-4: Anti-Infectious Drugs Session 6-5: Anti-Autoimmune Drugs     [i  M R m 猪q^O^B^h!>hv60JB*phh!>hv60JOJQJ^J%jh!>hv60JOJQJU^J$h!>h6CJKHOJQJ^JaJ#h!>h66CJOJQJ^JaJ#h!>hv66CJOJQJ^JaJ h!>h6CJOJQJ^JaJ h!>h_$CJOJQJ^JaJ#h!>hv6CJH*OJQJ^JaJ$h!>hv6CJKHOJQJ^JaJ h!>hv6CJOJQJ^JaJR "'_:|>$a$gd!>$a$gd!>ddd1$[$\$gd!>gd!>ddd1$[$\$gdm^gdm^gdv6  Q R Z  ? T Y % 6 N y   $%2:>rvɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶɶ}ɶ$h!>haCJKHOJQJ^JaJ$h!>hK3CJKHOJQJ^JaJ$h!>h6CJKHOJQJ^JaJ$h!>h6CJKHOJQJ^JaJ$h!>hv6CJKHOJQJ^JaJ!h!>0JCJOJQJ^JaJo($h!>hv60JCJOJQJ^JaJ1->MNR`d{%0!wxy':ɹɦɦududud h!>!>䴳ϴ#!>!>5Cϴ!>!>䴳(ϴ!>!>5Oϴ$!>!>䴳ϴ!>䴳ϴ!!>䴳ϴ($!>󳾰䴳ϴ$!>6䴳ϴ#>?<]*LU $Ifgdp`$a$gd!>gd!>:~l8gd!>$a$gd!>`kd$$If0FB t62 x2234Baytp`##$$$$$$$$$$$$ԳԮhp`jhp`U h!>h!> heo(h!>CJOJQJ^JaJo(#h!>h!>5CJOJQJ^JaJ h!>h!>CJOJQJ^JaJ4h!>h!>B*CJOJQJ\^JaJmH phsH &Z#Hy!S* h !]!!! "E"~"""$a$gd!>gd!>"'#u####$3$^$$$$$$$$$$$$$$$gdv6$a$gd!>gd!>6182P:pe. A!"#$%S $$If!vh55#v#v:V t6552 x2234 Bytp`j 666666666vvvvvvvvv666666>666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ OJPJQJ_HmH nHsH tHR`R v6cke $1$a$(CJKHOJQJ_HaJmH nHsH tH$A`$ ؞k=W[SOBi@B 0nfh*CJOJQJS*Y(^JaJo(phF"OA" v6trans.R. v60yblFhe,gCJaJDaD v60 yblFhe,g CharCJOJPJQJ^JaJPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!mQtheme/theme/theme1.xmlYMoE#F{oc'vGuرhF[x=ޝzvg53NjHHzZ $ʯI)*E_N&IA!>Ǽ3xN>鱫WL0Č߫߿z}rx{h9T8T/χ?xY'~3S~O_|w)ӈHt=a+d NG1-RlƁ1RJwT蠯M1K"o he˓ێ½PL-|%EhY7'qP.\L=dqķ3Iofi.ñBRb-JP_pG ݢiKtdӌhFio7;7Q2ȾD>a/Q>XW ˔M_uHq)h +:Viw4rBqϫ"r!2laCbU|!8^8>ܠ,AбVt׎~ls14_=,ɬožTV G"ѦbH'.4x޵w-ϷE|F;v`b3"G 'e\fHO '$i_wp >*8i&LY%\,xҕ= r6f 3Tʅ):ªZKLs&C Mܛ0 [˫p@ע`j۽7 YHxHicT5Ar@HZAZC}i' RQ\m,zo,gQu{Y\,Nר/=L _.̇Y7C6-fSh62"5NHT[X65̫4X%Yֳ2fkhi~tCKF#b +w1m|4`!:U!p5a:~{4mmio ήc8mDJpSǹ橠V1?#Si?3E'pS2W`qB]( 08w nA[s)k8= Aa?R dڒɾcUӽ˲d)#Queb}C!&i0>4S7{z F} 4sKvUKoȳh~1jYUVH5U8Vk;֜L9ŰD ?*|FL "A3>]2ֵ褽mg 8  $>"$X@  @H 0(  0(  B S  ? l { L U M\^l|}7@k}3<%7K\ 1 5 3333y  2  :A W!>_$ .K3v66O:0j;sI RjtRFdSV[ b(h/nFWnLG{H{~. eR5p`0a.mm^*;O+qKYa9aW ; zvC6C@ O @UnknownG*Ax Times New Roman5Symbol3. *Cx Arial7.{ @Calibri;([SOSimSunA BCambria Math 1hXfh:& F`4F`4!?!%),.:;>?]}    & 0 2 3 : !6"000 0 0 0000006:>@DZ\^ =@\]^$([{  0 0 000000Y[];[2qHX $Pv62!xxAnnietoshibaOh+'0T    (4<DLAnnieNormaltoshiba10Microsoft Office Word@NZ@xP&@X\/F`՜.+,D՜.+, X`lt| 4  8@ _PID_HLINKSA`l`javascript:void(0)}  !"#$&'()*+,-./012346789:;<>?@ABCDGRoot Entry Fp$\/IData 1Table%WordDocument88SummaryInformation(5DocumentSummaryInformation8=CompObju  F#Microsoft Office Word 97-2003 ĵ MSWordDocWord.Document.89q